Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer

International Journal of Biological Markers

Volumn 18, Issue 4, 2003, Pages 295-300

  Massacesi, Cristian ^a   Rocchi, M B L ^b   Marcucci, F ^a   Pilone, A ^a   Galeazzi, M ^c   Bonsignori, M ^a  

^a Oncol/Radiother Dept of Ancona   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c Pathology Department of Ancona   (Italy)

Author keywords

Clinical benefit; Doce taxl; Metastatic solid tumor; Prediction of response; Serum tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CHI SQUARE TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; PERIPHERAL EDEMA; PREDICTION; QUALITATIVE ANALYSIS; RATING SCALE; SKIN TOXICITY; SOLID TUMOR;

EID: 1242319465     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3624     Document Type: Article

References (22)

1. Dong Y, Walsh MD, Cummings MC, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997; 183: 311-7.
2. Giuntoli RL, Rodriguez GC, Whitaker RS, et al. Mucin gene expression in ovarian cancer. Cancer Res 1998; 58: 5546-50.
3. Bast RC, Radvin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2000; 19: 1865-78.
4. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 253: 2061-7.
5. Hardly JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 1989; 60: 764-6.
6. Rothenberg NIL, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53.
7. Burns III HA, Moore MJ, Andersen J, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
8. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93.
9. Fields-Jones S, Koletsky A, Wilding G, et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999; 10: 1307-10.
10. Lorusso V, Carpagnano F, Frasci G, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol 2000; 18: 405-11.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
12. Miller A, Hoogstraten B, Staquent M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
13. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70: 213-20.
14. Fleiss JE, Cohen J, Everitt BS. Large sample standard errors of kappa and weighted kappa. Psychol Bull 1969; 72: 323-7.
15. Landis RJ, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1997; 33: 159-74.
16. Ritts RE Jr, Nagorney DM, Jacobsen DJ, Talbot RW, Zurawski VR Jr. Comparison of preoperative serum CA 19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gall-bladder disease. Pancreas 1999; 9: 707-16.
17. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-91.
18. Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997; 20: 348-53.
19. Safi F, Kuhns V, Beger HG. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer. Int J Biol Markers 1995; 10: 100-6.
20. Kabawat SE, Bast RC, Bahan AK, et al. Tissue distribution of coelomic epithelium related antigen recognized by the monoclonal antibody OC125. Int J Gyn Pathol 1983; 2: 275-85.
21. Rustin GJS, Nelstrop AE, Mcclean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-51.
22. Jorgensen LG, Osterlind K, Genolla J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996; 74: 463-7.